Moderator Dr. Yun Sang Chan, Samson Consultant Urologist, Tuen Mun Hospital, Hong Kong (H.K.) Member of Urology Specialty Group, Central Coordinating Committee (COC) (Surgery) & the Surgical Outcomes Monitoring & Improvement Programme (SOMIP...
Erectile dysfunction (ED) is the inability to achieve or maintain a rigid penile erection suitable for satisfactory sexual intercourse, which substantially reduces the quality of life for patients and their partners. While ED prevalence increases wi...
Prostate cancer (PCa) is a complex disease that affects millions of males, globally. It is the 3rd most common cancer in males and the 4th leading cause of male cancer-related deaths in Hong Kong1. The aetiology of PCa is believed to be related to s...
AKEEGA™ (niraparib and abiraterone acetate) JOHNSON & JOHNSON HK Reg. No. HK-68296 (09 Jul, 2024) & HK-68295 (09 Jul, 2024) Composition: 2 AKEEGA™ is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, an...
The Uro-Oncology Asia 2021 Significant advances in urological cancer treatments have been emerging in recent years. For instance, immunotherapy continues to play an increasingly important role and innovations in biomarkers help select patients for s...
Erectile dysfunction can reduce sexual intimacy and negatively influence the psychological well-being in both the affected men and their partners. Besides, erectile dysfunction can be an early sign of cardiovascular disease, especially in younger me...
